Loading patent…
AssigneeSol-Gel Technologies Ltd.
InventorsMoshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO, Karine NEIMANN
Estimating the term…
Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.
A method of treating, preventing or alleviating non-melanoma skin cancer, wherein the method comprises topical administration to a subject in need thereof a therapeutically effective amount of a topical composition comprising erlotinib or a pharmaceutically acceptable salt thereof in a concentration of about 0.1% w/w to about 20% w/w.
A topical composition comprising erlotinib or a pharmaceutically acceptable salt thereof in a concentration of about 3.5%-7.5% w/w, and a pharmaceutically acceptable carrier, wherein administration of said composition does not induce or induces reduced cutaneous side-effects as compared with systemic administration of the same amount of erlotinib or pharmaceutically acceptable salt thereof and wherein said administration does not induce cutaneous toxicity or induces reduced cutaneous toxicity of erlotinib or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.